RaQualia Pharma Inc.

RaQualia Pharma Inc. is a pharmaceutical company engaged in research and development of compounds worldwide. Its human health portfolio includes tegoprazan for gastroesophageal reflux disease, grapiprant for cancer and pain management, RQ-00000008 for osteoarthritis and autoimmune disorders, and RQ-00000010 for gastroparesis. The company also develops veterinary products, such as capromorelin for anorexia in dogs and weight management in cats, and grapiprant for osteoarthritis in dogs. Incorporated in 2008, RaQualia Pharma is headquartered in Nagoya, Japan.